| Popis: |
The aim of this study was to screen the antimicrobial activity of a pyrimidine compound under the laboratory code VMA-21-01. Antimicrobial activity was studied in relation to: Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumonia, and Proteus mirabilis. The antimicrobial activity of 2,2-[6-Bromo-2,4-dioxoquinazoline- 1,3(2H)diyl]bis(N-carbamimidoylacetamide) was carried out in vitro by serial dilution and determination of its minimum inhibitory concentration. The sensitivity of microorganisms to the test substance was determined in a meat-peptone broth (visual assessment), followed by reinoculation on meat-peptone agar and colony count. DMSO tubes were used as a control. A 4% gentamicin solution was used as a comparison drug. In an in vitro experiment, it was found that the pyrimidine compound 2,2-[6-Bromo-2,4-dioxyquinazoline-1,3(2H)diyl]bis(N-carbamimidoylacetamide) under the laboratory cipher VMA21-01 has bactericidal activity against K. pneumonia comparable to the comparison drug gentamicin, as well as bacteriostatic activity against S. aureus, S. pneumoniae, E. coli, and P. mirabilis. |
